Literature DB >> 3825930

Significance of silent myocardial ischemia during exercise testing in patients with coronary artery disease.

D A Weiner, T J Ryan, C H McCabe, S Luk, B R Chaitman, L T Sheffield, F Tristani, L D Fisher.   

Abstract

To evaluate the significance of ischemic ST-segment depression without associated chest pain during exercise testing, data were analyzed from 2,982 patients from the Coronary Artery Surgery Study (CASS) registry who underwent coronary arteriography and exercise testing and were followed up for 7 years. Patients with proved coronary artery disease (CAD) (at least 70% diameter narrowing) were grouped according to whether they had at least 1 mm of ST-segment depression or anginal chest pain during exercise testing. Four hundred twenty-four had ischemic ST depression without angina (group 1); 232 had angina but no ischemic ST depression (group 2); 456 had both ischemic ST depression and angina (group 3); and 471 had neither ischemic ST depression nor angina (group 4). Sixty-three percent of patients in group 1 and 55% in group 2 had multivessel CAD (difference not significant). The 7-year survival rates were similar for patients in groups 1 (76%), 2 (77%), and 3 (78%), but were significantly better for patients in group 4 (88%, p less than 0.001). Among group 1 patients, survival was related to severity of CAD (p less than 0.001). The 7-year survival rate in group 1 was significantly worse than that in a separate group of 282 patients with ischemic ST depression without angina during exercise testing who had no CAD (95% survival, p less than 0.001). Thus, in patients with silent myocardial ischemia during exercise testing, the extent of CAD and the 7-year survival rate are similar to those of patients with angina during exercise testing. Prognosis is determined primarily by the severity of CAD. In patients without CAD, the survival rate is excellent.

Entities:  

Mesh:

Year:  1987        PMID: 3825930     DOI: 10.1016/0002-9149(87)91081-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

1.  Acute heavy alcohol intake increases silent myocardial ischaemia in patients with stable angina pectoris.

Authors:  J Rossinen; J Partanen; P Koskinen; L Toivonen; M Kupari; M S Nieminen
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 2.  Silent myocardial ischaemia. Implications for therapy.

Authors:  N G Uren; D P Lipkin
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 3.  Silent myocardial ischemia: recent developments.

Authors:  Peter F Cohn
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 4.  Indications for treatment of silent myocardial ischemia.

Authors:  P F Cohn
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

Review 5.  Silent myocardial ischaemia.

Authors:  S Campbell
Journal:  BMJ       Date:  1988-09-24

Review 6.  Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment.

Authors:  Akif Serhat Balcıoğlu; Haldun Müderrisoğlu
Journal:  World J Diabetes       Date:  2015-02-15

Review 7.  Daily life cardiac ischaemia. Should it be treated?

Authors:  B D Bertolet; C J Pepine
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 8.  Total ischemic burden in patients with coronary artery disease.

Authors:  J E Deanfield
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

9.  Sustained reduction of exercise perfusion defect extent and severity with isosorbide mononitrate (Imdur) as demonstrated by means of technetium 99m sestamibi.

Authors:  H C Lewin; R Hachamovitch; A G Harris; C Williams; J Schmidt; M Harris; K Van Train; G Siligan; D S Berman
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

10.  Silent myocardial ischemia is associated with altered plasma phospholipids.

Authors:  Hailong Lin; Jing Zhang; Peng Gao
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.